Add Formweb to your mobile device
Approved Formulary
Search results for:
metFORMIN-pioglitazone
metFORMIN-pioglitazone
Brand names: Actoplus Met, Actoplus Met XR
No brands, forms, or strengths have been added for this generic.
Medication comments:
| Per policy, orders for these non-formulary agents will be changed to formulary equivalents. | |
|---|---|
| Non-Formulary Agent | Formulary Equivalent |
| metFORMIN-pioglitazone (Actoplus Met) | pioglitazone (Actos) plus metFORMIN at same dose and frequency |
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | pioglitazone (Actos) |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | thiazolidinediones ⇄ Heart failure |
| Rationale | Potential to promote fluid retention and/or exacerbate heart failure. |
| Recommendation | Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure. |
| Quality of evidence: High, Strength of Recommendation: Strong | |
Last updated: Sep. 19, 2025
- Therapeutic Interchange Policy pioglitazone (Actos)
- Therapeutic Interchange Policy metFORMIN (Glucophage)
- Black Box Warnings metFORMIN: Lactic Acidosis
- Black Box Warnings pioglitazone: Congestive heart failure